BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist

Reuters

2024-12-18

BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist

Dec 18 (Reuters) - Merck & Co Inc MRK.N:

MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONIST
MERCK & CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONES
MERCK & CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024
MERCK & CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024

Source text: ID:nBw8jztsha

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492904299"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492904299\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492904299?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492904299","market":"us","top_or_hot":-1,"title":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Merck &amp; Co Inc <span>MRK.N</span>:</p><ul><li><p>MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONIST</p></li><li><p>MERCK &amp; CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONES</p></li><li><p>MERCK &amp; CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024</p></li><li><p>MERCK &amp; CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024</p></li></ul><p>Source text: <span>ID:nBw8jztsha</span></p><p>Further company coverage: <span>MRK.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-12-18 19:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor Agonist</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Merck &amp; Co Inc <span>MRK.N</span>:</p><ul><li><p>MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONIST</p></li><li><p>MERCK &amp; CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONES</p></li><li><p>MERCK &amp; CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024</p></li><li><p>MERCK &amp; CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024</p></li></ul><p>Source text: <span>ID:nBw8jztsha</span></p><p>Further company coverage: <span>MRK.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0006306889.USD","symbol_name":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABPDZLX:1","article_id":"2492904299","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492904299","pubTimestamp":1734522399,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor AgonistDec 18 (Reuters) - Merck & Co Inc MRK.N:MERCK ENTERS INTO EXCLUSIVE GLOBAL ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4559":"巴菲特持仓","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","MRK":"默沙东","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","BK4588":"碎股","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","BK4007":"制药","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","03692":"翰森制药","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK4516":"特朗普概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK1589":"北水核心资产","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC"},"translate_title":"简介-默克与翰森制药就研究性口服GLP-1受体激动剂签订全球独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"MRK":0.9},"content_text":"BRIEF-Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For Investigational Oral GLP-1 Receptor AgonistDec 18 (Reuters) - Merck & Co Inc MRK.N:MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH HANSOH PHARMA FOR INVESTIGATIONAL ORAL GLP-1 RECEPTOR AGONISTMERCK & CO INC - HANSOH PHARMA TO RECEIVE $112 MILLION UPFRONT, UP TO $1.9 BILLION IN MILESTONESMERCK & CO INC - MERCK WILL RECORD A PRE-TAX CHARGE OF $112 MILLION, OR $0.04 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN Q4 OF 2024MERCK & CO INC - TO RECORD $112 MILLION PRE-TAX CHARGE IN Q4 2024Source text: ID:nBw8jztshaFurther company coverage: MRK.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}